Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice

Abstract

included 182 patients with r/r B-ALL, their age was from one to 72 years old. 128 patients were treated with blinatumomab, 54 patients received inotuzumab ozogamicin. Overall response was high in both groups, 96 (75%) and 44 (82%). Th e major predictors of response were adult age (OR= 3.819; 95% CI, 1.744-8.223; p=0.001) and clinical indications, i.e., active disease or measurable residual disease (OR= 0.018; 95% CI, 0.153-0.841; p=0.01). Th e other clinical or disease parameters had no signifi cant impact on response. Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice. Cell Th er Transplant 9(1):